Vistagen announces publication in cns spectrums detailing proposed mechanism of action of its investigational neuroactive nasal sprays for anxiety and depression disorders

Dr. louis monti, vistagen's newly-appointed vice president, translational medicine, and dr. michael liebowitz, vistagen cns clinical and regulatory advisory board member, collaborate on review dr. louis monti, vistagen's newly-appointed vice president, translational medicine, and dr. michael liebowitz, vistagen cns clinical and regulatory advisory board member, collaborate on review
VTGN Ratings Summary
VTGN Quant Ranking